Abstract S1-3: A Comparison of Fulvestrant 500 mg with Anastrozole as First-Line Treatment for Advanced Breast Cancer: Follow-Up Analysis from the ‘FIRST’ Study

作者
J.F.R. Robertson,JPO Lindemann,Antonio Llombart‐Cussac,Janusz Rolski,David Feltl,J Dewar,Laura Emerson,A. Dean,MJ Ellis
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:70 (24_Supplement): S1-3 被引量:29
标识
DOI:10.1158/0008-5472.sabcs10-s1-3
摘要

Abstract Background: Fulvestrant 250 mg has been shown to be at least as effective as anastrozole as second-line endocrine therapy for advanced hormone receptor-positive (HR+) breast cancer. However, there are biological and clinical data suggesting that fulvestrant 500 mg is more effective than 250 mg. The Fulvestrant First-Line Study Comparing Endocrine Treatments (FIRST) was designed to compare fulvestrant 500 mg with anastrozole in the first-line setting. The primary analysis reported that fulvestrant 500 mg was at least as effective as anastrozole in terms of clinical benefit rate and objective response rate. At data cut-off for the primary analysis, performed 6 months after the last patient (pt) was randomized, 117 (57.1%) pts were receiving study treatment, and median time to progression (TTP) was not reached for fulvestrant 500 mg vs 12.5 months for anastrozole (HR 0.63; 95% CI 0.39, 1.00; p=0.0496). Here, we report a follow-up data analysis of TTP and time to treatment failure (TTF). Methods: This was a Phase II, randomized, open-label, multicenter study comparing fulvestrant 500 mg (500 mg i.m. on Day 0, then 500 mg i.m. on Days 14 and 28 and every 28 days thereafter) with anastrozole (1 mg/day p.o.) as first-line treatment for postmenopausal women with advanced breast cancer. Follow-up analysis was performed when 79.5% of pts had discontinued study treatment. TTP was defined by RECIST before data cut-off for the primary analysis, and investigator opinion after data cut-off. TTF was defined as time from randomization to cessation of trial therapy. In the fulvestrant 500 mg group, TTF was derived as last injection plus 14 days, representing the midpoint in the window where treatment was withdrawn. Best overall response to first subsequent breast cancer therapy, WHO-PS, and serious AEs are also reported. Results: A total of 205 pts received fulvestrant 500 mg (n=102) or anastrozole (n=103). At this follow-up analysis with data cut-off March 26 2010, median follow-up for TTP across both treatment groups was 16.5 months. Median TTP was 23.4 months for the fulvestrant 500 mg group vs 13.1 months for the anastrozole group, corresponding to a 35% reduction in risk of progression (HR 0.66; 95% CI 0.47, 0.92; p=0.01). Median TTF was 17.6 months vs 12.7 months for the fulvestrant 500 mg and anastrozole groups, respectively (HR 0.73; 95% CI 0.54, 1.00; p=0.05). The best overall response to subsequent therapy was similar between the treatment groups (including 15 pts [23.8%] in the fulvestrant 500 mg group and 15 pts [21.1%] in the anastrozole group with either a complete or partial response) and there were no clinically important differences in terms of WHO-PS. Fulvestrant 500 mg was well tolerated and no new safety concerns were documented. Conclusion: With significantly longer follow-up, the TTP and TTF results from this analysis are consistent with the analysis of TTP at the primary data cut-off. Taken together, these results suggest an efficacy benefit for fulvestrant 500 mg compared with anastrozole as first line endocrine therapy for pts with HR+ advanced breast cancer. These data provide further support that if fulvestrant is used in advanced breast cancer then the preferred dose should be 500 mg. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr S1-3.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
有流量发布了新的文献求助30
1秒前
godman605完成签到 ,获得积分10
1秒前
2秒前
石瑶完成签到,获得积分10
2秒前
顾矜的应助被Xin5599采纳,获得10
3秒前
陈_Ccc完成签到 ,获得积分10
3秒前
66Ku完成签到,获得积分10
4秒前
哈哈哈完成签到 ,获得积分10
4秒前
4秒前
夏天完成签到,获得积分10
4秒前
5秒前
科研小白发布了新的文献求助10
5秒前
鲤鱼鑫磊发布了新的文献求助10
5秒前
godman605关注了科研通微信公众号
6秒前
美丽发布了新的文献求助20
6秒前
豚豚完成签到,获得积分10
7秒前
7秒前
hhh完成签到,获得积分10
8秒前
一颗荔枝完成签到,获得积分10
9秒前
Monica发布了新的文献求助10
10秒前
zejuLong完成签到 ,获得积分10
10秒前
英俊的铭的应助被JerryPanJ采纳,获得10
11秒前
11秒前
一尾胖头鱼完成签到,获得积分10
12秒前
今后的应助被白华苍松采纳,获得10
12秒前
12秒前
星辰大海的应助被沦落而采纳,获得10
13秒前
muzi完成签到,获得积分10
13秒前
14秒前
阿九完成签到,获得积分10
14秒前
Lucas的应助被第三方公司采纳,获得10
15秒前
15秒前
健忘曼彤完成签到,获得积分10
16秒前
大气的杨完成签到 ,获得积分10
16秒前
16秒前
17秒前
18秒前
今后的应助被HHH采纳,获得10
18秒前
晴晴发布了新的文献求助10
18秒前
畅快往事发布了新的文献求助10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187362
求助须知:如何正确求助?哪些是违规求助? 9575478
关于积分的说明 21841431
捐赠科研通 7785067
什么是DOI,文献DOI怎么找? 3434943
关于科研通互助平台的介绍 2559401
邀请新用户注册赠送积分活动 2481820